Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis

BACKGROUND: Adding carboplatin to weekly paclitaxel as part of neoadjuvant chemotherapy (NACT) for stage II–III triple negative breast cancer (TNBC) has been shown to significantly increase the pathologic complete response (pCR) rate. Hematologic toxicities associated with every 3-week dosing of car...

Descripción completa

Detalles Bibliográficos
Autores principales: Landry, Kara K, Lyon, Jessica L, Victoria, Kitty E, Changizzadeh, P Nick, Cole, Bernard F, Pulluri, Bhargavi, Sikov, William M, Wood, Marie E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934152/
https://www.ncbi.nlm.nih.gov/pubmed/35313558
http://dx.doi.org/10.2147/BCTT.S342635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934152/
https://www.ncbi.nlm.nih.gov/pubmed/35313558
http://dx.doi.org/10.2147/BCTT.S342635

Ejemplares similares